Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.38 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL833877 | 0.81 | SHBG (0.47) | SHBGGRIN2BNR3C1PGRAR | |
| SCHEMBL27620448 | 0.81 | SHBG (0.47) | SHBGGRIN2BNR3C1PGRAR | |
| SCHEMBL29948191 | 0.81 | SHBG (0.47) | SHBGGRIN2BNR3C1PGRAR | |
| Hydrochloric Acid SCHEMBL29820142 | 0.76 | SLC6A4 (0.40) | DPP4F2 | |
| SCHEMBL27337905 | 0.76 | SHBG (0.50) | SHBGGRIN2BCYP17A1HSD17B1HSD17B2 | |
| SCHEMBL17073532 | 0.76 | IDO1 (0.41) | DPP4F2 | |
| SCHEMBL17064503 | 0.76 | IDO1 (0.41) | DPP4F2 | |
| SCHEMBL29580817 | 0.76 | IDO1 (0.41) | DPP4F2 | |
| SCHEMBL27595703 | 0.76 | ALOX15 (0.43) | DPP4F2 | |
| SCHEMBL27965911 | 0.75 | PTGS1 (0.43) | SHBGGRIN2BNR3C1PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021003295-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |